HAEMONETICS CORP/MASS (HAE) Stock Overview
USA - NYSE:HAE - US4050241003 - Common Stock
HAE Key Statistics, Chart & Performance
The current stock price of HAE is 49.99 USD. In the past month the price increased by 1.29%. In the past year, price decreased by -30.83%.
HAE Latest News, Press Relases and Analysis
HAE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 24.59 | 37.11B | ||
| COO | COOPER COS INC/THE | 17.44 | 13.94B | ||
| SOLV | SOLVENTUM CORP | 11.39 | 12.01B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.32 | 10.03B | ||
| BLCO | BAUSCH + LOMB CORP | 35.21 | 5.36B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.69 | 4.92B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.68 | 3.77B | ||
| ICUI | ICU MEDICAL INC | 15.92 | 2.96B | ||
| XRAY | DENTSPLY SIRONA INC | 7.36 | 2.51B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.47B | ||
| UFPT | UFP TECHNOLOGIES INC | 21.47 | 1.43B | ||
| NEOG | NEOGEN CORP | 20 | 1.30B |
Related stock screener links
About HAE
Company Profile
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Company Info
HAEMONETICS CORP/MASS
125 Summer Street
Boston MASSACHUSETTS 02110 US
CEO: Christopher A. Simon
Employees: 3657
Phone: 17818487100
HAEMONETICS CORP/MASS / HAE FAQ
What does HAEMONETICS CORP/MASS do?
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. The firm is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
What is the current price of HAE stock?
The current stock price of HAE is 49.99 USD. The price increased by 1.11% in the last trading session.
Does HAEMONETICS CORP/MASS pay dividends?
HAE does not pay a dividend.
What is the ChartMill rating of HAEMONETICS CORP/MASS stock?
HAE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What sector and industry does HAEMONETICS CORP/MASS belong to?
HAEMONETICS CORP/MASS (HAE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the market capitalization of HAE stock?
HAEMONETICS CORP/MASS (HAE) has a market capitalization of 2.41B USD. This makes HAE a Mid Cap stock.
Can you provide the short interest for HAE stock?
The outstanding short interest for HAEMONETICS CORP/MASS (HAE) is 7.01% of its float.
HAE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HAE. When comparing the yearly performance of all stocks, HAE is a bad performer in the overall market: 93.34% of all stocks are doing better.
HAE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HAE. While HAE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
HAE Financial Highlights
Over the last trailing twelve months HAE reported a non-GAAP Earnings per Share(EPS) of 4.65. The EPS increased by 17.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.13% | ||
| ROA | 6.63% | ||
| ROE | 18.51% | ||
| Debt/Equity | 1.04 |
HAE Forecast & Estimates
15 analysts have analysed HAE and the average price target is 81.91 USD. This implies a price increase of 63.84% is expected in the next year compared to the current price of 49.99.
For the next year, analysts expect an EPS growth of 6.66% and a revenue growth -4.81% for HAE